PrintContact
 
  • Home
  • About Us
  • Sativex
  • R&D
  • Investors
  • Media
GW Pharmaceuticals
  • UK Launch
  • Summary of Product Characteristics
  • Therapeutic Uses
  • Prescriber Information
  • Mechanism of Action
  • Clinical Trials
  • Publications
  • Partners
  • Patient Organisations
  • Sativex FAQs
  • Home
  • Sativex

Sativex

Sativex® is a cannabinoid medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain and neuropathic pain of various origins...

 

Now-approved-in-the-UK

Please click here for more information regarding the
launch of this medicine

 

 

Therapeutic Uses

  • Multiple Sclerosis
  • Cancer Pain
  • Neuropathic Pain
  • Other

 

Prescriber Information

Information for physicians on the availability of Sativex in different countries.

Clinical Trials

Information for potential participants in ongoing trials and summary of completed trials.

 

Publications

Details of peer-review publications from completed clinical trials of Sativex. 

Partners

GW has partnered with companies to market Sativex in countries around the world.

 

Mechanism Of Action

Pharmacology of Sativex and how its principal active components act in the body.

 

Please note that we cannot provide advice on the suitability of Sativex for individual patients.
Patients wishing to know more about Sativex should discuss with their doctor the most suitable treatment for them.

 
 
 

© GW Pharmaceuticals 2009

  • Home
  • Sitemap
  • Accessibility
  • Disclosure & Disclaimer
  • Contact
  • Email Alerts
 

Website designed and developed by www.emperordesign.co.uk